represent an appealing source of circulating ES-specific analytes.
In the majority of patients (85%), these translocations involve fusion of the DNA binding domain of the ES breakpoint region 1 (EWSR1) with the transactivation domain of FLI1, a member of the E26 transformation-specific (ETS) family of transcription factors. 8, 9 EWS-FLI1 (11;22)(q24;q12) gene fusions exist in two known variant groups: type 1 fusions (60% of all EWS-FLI1 cases), in which EWS exons 1-7 are fused to FLI1 exons 6-9; and type 2 fusions, in which EWS exons 1-7 join FLI1 exons 5-9. Alternative translocations have also been described involving EWS and other ETS family members (ERG, FEV, ETV1, E1AF, etc.), but they are exceedingly rare, in that the next most common rearrangement accounts for less than 10% of all ES cases. 10, 11 EWS rearrangements give rise to chimeric proteins that mediate aberrant oncogenic transcriptional programs and interfere with pivotal signaling pathways involved in cell growth, differentiation and proliferation. 11 This quintessential role of EWS fusion transcripts makes it highly unlikely that they might be counter-selected, down-regulated or lost during tumor progression, strongly supporting their routine diagnostic assessment not only in genomic DNAs from ES tumor tissues, 12, 13 but also in a 'liquid biopsy' (LB) format, for example for the convenient, non-invasive, longitudinal monitoring of aberrant genomic traits in blood (reviewed by Siravegna and colleagues 14 ). Yet, to our knowledge there are only two published papers on LB in ES. In the first paper, Hayashi and colleagues designed a number of polymerase chain reaction (PCR) primers and probes to capture the complexity of EWS DNA breakpoint regions in circulating tumor DNA (ctDNA) from three patients. 15 In the second, very recent paper, one of us described the detection of EWS gene rearrangements in circulating tumor cells. 16 In the present study, we took a third, different approach involving chip-based digital PCR (dPCR) on plasma with the limited set of primers and probes recently shown by Benini and colleagues to detect circulating tumor cells. 16 These dPCR assays have been designed to directly identify fusion transcripts in tissues and circulating tumor RNA (ctRNA) regardless of patientspecific DNA breakpoints. We show herein that this simplified approach detects EWS-FLI1 translocations in patients whose clinical histories epitomize recurrent ES clinical queries. We show that, in combination with last-generation medical imaging [i.e. positron emission tomography (PET)], LB provides simple, integrative and informative readouts for non-invasive, longitudinal assessment of ES tumor burden.
Materials and methods

Patients characteristics and sampling
Biobanking and testing of biological materials were approved by the Central Ethical Review Board of the Italian National Cancer Institutes (CEC/707/15 dated 13 October 2015), and were conducted in compliance with the World Medical Association Declaration of Helsinki. Each participant signed a written informed consent authorizing the collection of genomic information (except germline, genome-wide data) from both tissues and blood, as well as anonymized data exchange/ dissemination exclusively for scientific, nonprofit purposes. The clinical characteristics of the patients are presented in Table 1 . Tumor tissue specimens were collected on the occasion of either surgery or diagnostic excisional biopsy. Upon histologic examination, all cases showed a typical ES phenotype with a small blue round cell morphology, an immunohistochemical intense membranous stain for CD99, nuclear positivity for FLI1, occasional staining for synaptophysin, and no detectable muscular, cytokeratin and lymphoid markers. Complementary DNAs (cDNAs) with and without known EWS rearrangement (from ES and non-ES specimens, respectively) were included as dPCR control templates. Blood specimens were collected in BD Vacutainer K 2 EDTA tubes (BD Biosciences, San Jose, CA, USA) at the indicated time points, and plasma was processed within 1 h by two successive rounds of centrifugation at 4°C (2000 × g for 20 min, and 16,000 × g for 10 min) to remove cells and residual debris, respectively. Cleared plasma samples were stored frozen at −80°C in 1.8 ml aliquots at the IRCCS Regina Elena National Cancer Institute Body Fluids Biobank (BBIRE-LB), and were thermally monitored until thawing and processing.
RNA extraction, quantification and retrotranscription
A total of four sections (5-µm thick) were cut from formalin-fixed, paraffin-embedded (FFPE) tissue blocks, macro-dissected for enrichment in 
RT-qPCR and dPCR
EWS-FLI1 translocations were analyzed essentially as described 16 The mix was loaded onto dPCR chips, and thermal cycling was as follows: an initial denaturation step of 10 min at 96.0°C, then 39 cycles for 2 min at 58.0°C and 30 sec at 98.0°C, followed by a final elongation step of 2 min at 60°C. Threshold values (positive versus negative; blue versus yellow spots) were automatically calculated by the ThermoFisher Cloud Analysis Suite in tissue RNA from each patient, manually reviewed, and then applied to ctRNA assays from the same patient with no additional data manipulation.
Integration of PET imaging and LB data
Volume-based PET parameters were calculated as described. 17 Overall, two semi-quantitative 
Results
Assay validation on FFPE-derived RNAs
The technical aim of the present study was to develop a robust and sensitive dPCR assay to quantitate EWS-FLI1 fusion transcripts in the bloodstream. To this end, previously designed 16 primer/probe sets were initially validated on five available RNAs isolated from FFPE tumor tissues of representative ES patients. Positive and negative controls (the latter including cDNAs from non-ES and no cDNA samples) were included in each run. EWS types 1 and 2 rearrangements were detected and concordantly assigned by RT-qPCR [ Figure 1 (a)] and dPCR [ Figure 1 (b)] in all 5 patients. Marginal dPCR noise (mean 1.2%; range 0.0-2.4%) was almost invariably seen of type 2 rearrangements in type 1 EWS assays, and vice versa. Remarkably, noise was seen in tissues (presumably because input cDNA is high in these samples), but not in plasma samples that contain low levels of ctRNA (see below). Thus, noise ranged from negligible to absent and it did not affect variant assignment. It is concluded that EWS types 1 and 2 transcripts can be distinguished by dPCR with high signal to noise ratios. Unlike RT-qPCR, dPCR absolute quantification (copy number per ml) does not require internal normalization controls. As expected, this results in a simpler and more precise assay format. Thus, dPCR was selected for LB assessment on four representative ES patients.
Detection of EWS rearrangements in ctRNAs from plasma samples
As shown in Figure 2a -c, an EWS type 2 rearrangement was clearly detectable, after adjuvant chemotherapy, in matched tissue and plasma RNAs obtained from pt#2. Blood was taken on the day before surgery. The positive LB assay was in agreement with a PET/computed tomography (CT) scans obtained 30 days earlier, and confirmed tissue molecular diagnosis. In addition, the presence of ctRNA in the bloodstream suggested the persistence of residual tumor lesions after chemotherapy.
In another case (pt#4, Figure 3 Altogether, these results demonstrate that ES patients can be monitored by LB in a variety of clinical situations, using just two sets of variantspecific dPCR primers detecting two prevalent EWS rearrangements.
Correlation between metabolic tumor uptake and ctRNA burden Finally, we looked for possible correlations between conventional volumetric PET parameters on the one hand, and copy numbers of EWS fusion transcripts in blood, on the other. MTV and TLG values were calculated by two different thresholds (SUV = 2 and 40% of SUV max ), and were paired with copy numbers of EWS transcripts, estimated by dPCR at each of the five time points for which both sets of data were available in four patients. High (>0.85) and statistically significant (p < 0.05) regression coefficients were obtained for MTV 2 , MTV 40% and TLG 40% , whereas a nonsignificant correlation trend was obtained for TLG 2 (Supplemental Figure S1) . Thus, the available data, although limited, suggest a functional link between PET volumetric parameters and the release of driver oncogenic fusions into the bloodstream. 
Discussion
ES is a very aggressive neoplasm that displays a marked propensity for local relapse and metastatic spread. It requires a variety of multimodal treatments and combinations, including intensive neoadjuvant and adjuvant chemotherapy, as well as surgery and radiotherapy. In the lack of tumorspecific, non-invasive diagnostic and prognostic tools, the detection of EWS fusions by LB during the clinical course of the disease may have a considerable value. LB is expected to: (a) place a molecular diagnosis at ES onset; (b) confirm molecular lesions upon progression; (c) rapidly assess clinical response to surgical and medical treatment; (d) correlate with, or even predict, relapse/response; and (e) objectively assess residual or progressive disease at follow up.
The present real-life study provides the first evidence that LB may gather information relevant to most of the above recurrent clinical queries. 15 is based on a highly customized, patientspecific, long-range droplet dPCR (ddPCR) assay. As also noted by the authors, its application to routine diagnosis bears two limitations. First, it requires next generation sequencing (NGS) from tumor tissues to grab the sequence information necessary to design ddPCR assays. Second, this NGS step works best with fresh tissue, since FFPE introduces some fragmentation in the long DNA templates necessary to capture heterogeneous translocation events. The approach by Benini and colleagues 16 and our own bypass the need to sequence patientspecific breakpoints, collect long tumor DNA fragments from fresh tissues, and design patient-specific primer sets. The assay described herein, in particular, takes advantage of plasma (and not circulating tumor cells), short ctRNA fragments as templates, and two sets of variant-specific primers. By these means, the identification of ES translocation is drastically simplified and becomes applicable even to outpatients (one example is described; pt#4) referred for therapy from other clinical centers with no molecular information, and no available pathological specimens. Along this line, one may foresee that our method will be ideal to retrospectively detect ES rearrangements in banked plasma collections. Most importantly, the use of a limited set of primer/probes for most ES patients renders our assay particularly valuable in the clinical pathological routine. Only side-by-side comparison may conclusively assess the relative merits and limitations of the approaches by Hayashi and colleagues, Benini and colleagues, and our own.
The major limitation of our own study (and other studies on rare ES tumors) is that we were not able to test large numbers of samples. In spite of this, we have shown that LB is clinically applicable to ES, and optimization efforts are warranted to yield a widely applicable and reliable assay to detect EWS ctRNAs and ctDNAs.
